Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima, Unknown

Open source

DOI
10.1007/s13555-023-00901-7
Published
2023-03-11
Container
Dermatology and Therapy
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s13555-023-00901-7,
  title = {Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial},
  author = {Kenji Kabashima and Takayo Matsumura and Hiroshi Komazaki and Makoto Kawashima and Unknown},
  year = {2023},
  journal = {Dermatology and Therapy},
  doi = {10.1007/s13555-023-00901-7},
  url = {https://doi.org/10.1007/s13555-023-00901-7}
}

RIS

TY  - JOUR
TI  - Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial
AU  - Kenji Kabashima
AU  - Takayo Matsumura
AU  - Hiroshi Komazaki
AU  - Makoto Kawashima
AU  - Unknown
PY  - 2023
JO  - Dermatology and Therapy
DO  - 10.1007/s13555-023-00901-7
UR  - https://doi.org/10.1007/s13555-023-00901-7
ER  - 

APA

Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M., & Unknown (2023). Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial. Dermatology and Therapy. https://doi.org/10.1007/s13555-023-00901-7

Source records